CorMedix Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
5analysts covering
FY EPS (est.)
$0.50next fiscal year
Monitoring Framework
Key Performance Indicators
DefenCath Net Revenue Quarterly97.5MTarget: 175000000 to 195000000
Total Net Revenue Quarterly127.4MTarget: 325000000 to 345000000
Adjusted EBITDA Quarterly70MTarget: 115000000 to 135000000
Watch Items
- TDAPA Expiration and Reimbursement TransitionTrigger: June 30, 2026 TDAPA expirationAction: Monitor outpatient dialysis pricing erosion and transition to post-TDAPA add-on structure by CMS for 2027 pricing improvements.
- REZZAYO sNDA SubmissionTrigger: Second half of 2026Action: Track preparation and submission of sNDA to the FDA following positive Phase III ReSPECT clinical trial topline results.
- TPN Study Enrollment TrajectoryTrigger: Slow enrollment trending toward 2028Action: Monitor the opening of new clinical study sites and the submission/approval of the protocol amendment to the FDA to remove certain exclusion criteria and broaden patient enrollment.
Research as of 19 Jun 2026